论文部分内容阅读
目的:总结近期国内外三阴性乳腺癌的靶向治疗研究进展。方法:应用Medline、Pub Med、Web of science、CNKI数据库,以“三阴性乳腺癌、基底样乳腺癌和靶向治疗”为关键词,搜索近期发表的相关临床研究。共纳入文献30篇。结果:大量临床试验发现,靶向表皮生长因子受体(EGFR)抑制药西妥昔单抗(单克隆抗体)能明显提高TNBC患者的总反应率(ORR)、无进展生存期(PFS)、总生存期(OS)或临床获益(CB);血管内皮生长因子(VEGF)抑制药贝伐珠单抗(单克隆抗体)不能延长患者OS,但能显著延长MBC/ABC患者的PFS和ORR,索拉非尼(小分子抑制剂)能改善TNBC患者的PFS;腺苷核糖聚合酶(PARP)抑制药olaparib,能使BRCA1/2基因突变的TNBC患者获益。结论:随着对TNBC生物学行为的深入研究,新的靶点不断被发现、新的靶向药物陆续面市,使TNBC治疗策略更完善。
Objective: To summarize the recent research progress of targeted therapy of triple negative breast cancer at home and abroad. Methods: Using the keywords “Medline, PubMed, Web of science and CNKI to search for” triple negative breast cancer, basal-like breast cancer and targeted therapy ", search for recent published clinical research. Thirty articles were included. Results: A large number of clinical trials found that targeting EGFR inhibitor cetuximab (monoclonal antibody) significantly increased the overall response rate (ORR), progression-free survival (PFS) (OS) or clinical benefit (CB). The VEGF inhibitor bevacizumab (monoclonal antibody) did not prolong the OS, but significantly prolonged the PFS and ORR in patients with MBC / ABC , Sorafenib (a small molecule inhibitor) can improve PFS in patients with TNBC; adenosine ribose polymerase (PARP) inhibitor olaparib, can make the BRCA1 / 2 mutations in patients with TNBC benefit. Conclusion: With the further study on the biological behavior of TNBC, new target sites were found continuously and new targeted drugs appeared one after another, which made TNBC treatment strategy more perfect.